Glaucoma

Approaching glaucoma patient care with a holistic view

Approaching glaucoma patient care with a holistic view

In caring for patients with glaucoma, ophthalmologists need to ask about systemic medical conditions and medications because certain findings in these histories have effects on IOP and glaucoma risk, said Gerhard Garhöfer, MD, at the ESCRS Glaucoma Day.

“It makes sense to look at our patients as a whole. We should not only concentrate on the eye,” said Dr Garhöfer, Medical University of Vienna, Austria.

Learning about a patient’s blood pressure (BP) and existing treatment for systemic hypertension is important, especially considering that almost one-third of the world’s adult population suffers from systemic hypertension.

“I am pretty sure that all of you have received questions from patients asking whether their systemic hypertension influences their glaucoma,” Dr Garhöfer noted. The answer is somewhat complicated, he said. Although the available data show a statistical association between increased BP and increased IOP, the association is very weak from a clinical point of view.

An effect of low systemic BP on glaucoma risk has also generated interest, considering evidence pertaining to relationships between systemic BP and ocular perfusion pressure and between ocular perfusion pressure and glaucoma. However, ocular perfusion pressure cannot be directly measured, and the take-home message for clinicians on this topic is to be aware that patients with a very high IOP and a low BP are at considerably increased risk for glaucoma.

For patients who are being treated for systemic hypertension, ophthalmologists should ascertain use of a beta-blocker.

“Be aware that patients receiving systemic treatment with a beta-blocker have an average 1.0 to 1.5 mmHg reduction in IOP,” Dr Garhöfer said. “Topical beta-blocker therapy for glaucoma may be less effective in patients on a systemic beta blocker, and taking oral and topical beta blockers together is associated with an increased risk for adverse effects.”

Ophthalmologists should also be aware that patients who are being treated aggressively for their systemic hypertension with the goal of managing cardiovascular risk may suffer from nocturnal dips in BP that have been shown to increase risk of glaucoma progression. Dr Garhöfer suggested obtaining 24-hour BP measurements in these individuals.

Regarding other systemic diseases, he noted that a variety of inflammatory and autoimmune systemic conditions can also involve ocular structures and lead to increased IOP. The list includes sarcoidosis, Bechet’s disease, HLAB27-related uveitis, juvenile idiopathic arthritis-associated uveitis, and Vogt-Koyanagi-Harada syndrome.

Considering that glaucoma prevalence increases with age, clinicians should recognise there is also an age-related increase in systemic medication use and that certain medications increase IOP.

“Two-thirds of adults aged 48 to 64 years, and 90% of people aged 65 years and older, take five or more medications,” Dr Garhöfer said. “Do not only ask patients what diseases they have, but also what medications they are taking.”

Corticosteroids, which are commonly used, represent the classic culprit, and this class of medications can lead to increased IOP regardless of the route of administration. Moreover, 30% of patients using corticosteroids experience an increase in IOP, and approximately 5% of individuals are “high responders,” meaning their IOP will increase significantly.

Tags: 40th Congress of the ESCRS
Latest Articles
Towards a Unified IOL Classification

The new IOL functional classification needs a strong and unified effort from surgeons, societies, and industry.

Read more...

Organising for Success

Professional and personal goals drive practice ownership and operational choices.

Read more...

Update on Astigmatism Analysis

Read more...

Is Frugal Innovation Possible in Ophthalmology?

Improving access through financially and environmentally sustainable innovation.

Read more...

iNovation Innovators Den Boosts Eye Care Pioneers

New ideas and industry, colleague, and funding contacts among the benefits.

Read more...

From Concept to Clinic

Partnerships with academia and industry promote innovation.

Read more...

José Güell: Trends in Cornea Treatment

Endothelial damage, cellular treatments, human tissue, and infections are key concerns on the horizon.

Read more...

Making IOLs a More Personal Choice

Surgeons may prefer some IOLs for their patients, but what about for themselves?

Read more...

Need to Know: Higher-Order Aberrations and Polynomials

This first instalment in a tutorial series will discuss more on the measurement and clinical implications of HOAs.

Read more...

Never Go In Blind

Novel ophthalmic block simulator promises higher rates of confidence and competence in trainees.

Read more...